Syneos Health, a contract research organization (CRO) and consulting firm, has signed a three-year service agreement with global pharmaceutical firm Pfizer. Under the terms of the agreement, Syneos Health will provide product development solutions to the drug company, with the option to extend for two additional years.
Prior to this newly signed agreement, the two companies had worked together frequently over the years. Syneos has a record of providing insights and advice regarding clinical research and commercial services to support development of various products. According to Syneos, this new agreement will continue that relationship, with the company providing service to Pfizer projects around the globe, covering a variety of therapeutic areas.
Paul Colvin, president of Syneos Health Clinical Solutions, said the pharmaceutical firm stands to benefit from his company’s range of capabilities and knowledge.
“Our ability to deliver deep therapeutic expertise, while bringing forward insights that can facilitate shorter and more efficient trials, has proven to be advantageous in our work with Pfizer,” he said. “This new agreement allows us to continue our collaboration to deliver flexible and innovative solutions."
“We are pleased to expand our Pfizer relationship to optimize their portfolio and deliver on our shared purpose to change patients’ lives,” Colvin added.
Earlier this year, Syneos Health senior vice president of real-world and late phase David Thompson spoke on the future of virtual/decentralized technology in clinical research and drug development.
In March, Pfizer joined Gilead, Merck, Novartis and other pharmaceutical giants on a COVID-19 solution collaboration, facilitated by the Bill and Melinda Gates Foundation.
